GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1205-1219

  Li, Yazhou ^a   Duffy, Kara B ^b   Ottinger, Mary Ann ^b   Ray, Balmiki ^c   Bailey, Jason A ^c   Holloway, Harold W ^a   Tweedie, David ^a   Perry, Tracyann ^a   Mattson, Mark P ^a   Kapogiannis, Dimitrios ^a   Sambamurti, Kumar ^d   Lahiri, Debomoy K ^c   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

3xTg AD mice; Alzheimer's disease; Amyloid peptide; Amyloid protein precursor; Dementia; Diabetes; Extendin 4; Glucagon like peptide 1; Neuroprotection; Streptozocin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; EXENDIN 4; EXENDIN 9-39; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; HUMAN; HUMAN CELL; MALE; NERVE CELL CULTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

EID: 77950352189     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1314     Document Type: Article

References (72)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503), 2112-2117.
3. Götz J, Ittner LM, Lim YA (2009) Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 66, 1321-1325.
4. Jin W, Patti ME (2009) Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes. Clin Sci (Lond) 116, 99-111.
5. Reddy VP, Zhu X, Perry G, Smith MA(2009) Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 16, 763-774.
6. Bennett S, Grant MM, Aldred S (2009) Oxidative stress in vascular dementia and alzheimer's disease: a common pathology. J Alzheimers Dis 17, 245-257.
7. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16, 693-704.
8. Toro P, Schönknecht P, Schröder J (2009) Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany. J Alzheimers Dis 16, 687-691.
9. Arvanitakis Z,Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61, 661-666.
10. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152.
11. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66, 300-305.
12. Jones A, Kulozik P, Ostertag A, Herzig S (2009) Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis 16, 787-808.
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
14. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1, 1-31.
15. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3, 81-90.
16. Alonso AC, Li B, Grundke-Iqbal I, Iqbal K (2008) Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res 5, 375-384
17. Calcutt NA, Cooper ME, Kern TS, Schmidt AM (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 8, 417-429.
18. Lovshin JA, Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5, 262-269.
19. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240-1250.
20. Kastin AJ and Akerstrom V (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27, 313-318.
21. Perry T, Greig NH (2003) The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 24, 377-383.
22. Hamilton A, Hölscher C (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20, 1161-1166.
23. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ,Wang Y, Greig NH (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106, 1285-1290.
24. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH (2002) A novel neurotrophic property of glucagonlike peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300, 958-966.
25. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302, 881-888.
26. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH(2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72, 603-612
27. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Rönnholm H,Wikström L (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86, 326-338.
28. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflam 21, 5-19.
29. Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328.
30. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9, 1173-1179.
31. Abbas T, Faivre E, Hölscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 205, 265-271.
32. Gault VA, Hölscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587, 112-117
33. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular abeta and synaptic dysfunction. Neuron 39, 409-421.
34. Billings LM, Green KN, McGaugh JL, LaFerla FM (2007) Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci 27, 751-761.
35. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al. (2001) Earlyonset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276, 21562-21570.
36. Lahiri DK, Chen D, Bondy SC, Sharman EH (2004) Dietary supplementation with melatonin reduced levels of amyloid beta-peptides in mice brain. J Pineal Res 36, 224-231.
37. Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, Banerjee PK, Lahiri DK (2010) Memantine lowers amyloid beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 88, 143-154.
38. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi- Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y (2008) Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 1216, 92-103.
39. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, et al. (1999) Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53, 1992-1997.
40. Wessels AM, Scheltens P, Barkhof F, Heine RJ (2008) Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol 585, 88-96.
41. Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26, 1044-1080.
42. Mattson MP (2009) Roles of the lipid peroxidation product 4- hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol 44, 625-633.
43. Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R,Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
44. Neumann KF, Rojo L, Navarrete LP, Faŕas G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 5, 438-447.
45. Sabayan B, Foroughinia F, Mowla A, Borhanihaghighi A (2008) Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review. Am J Alzheimer's Dis Other Demen 23, 192-199.
46. Freude S, Schilbach K, Schubert M (2009) The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 6, 213-223.
47. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM,Schellenberg GD, Frey WH2nd, Craft S (2008) Intranasal insulin administration dosedependently modulates verbal memory and plasma amyloidbeta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
48. Banks WA, Jaspan JB, Huang W, Kastin AJ (1997) Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18, 1423-1429.
49. Perry T, Holloway HW,Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203, 293-301.
50. Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA, Zhu X (2008) Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 5, 525-532.
51. Gispen WH, Biessels G J (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23, 542-549.
52. Kamal A, Biessels GJ, Urban IJ, Gispen WH (1999) Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of longterm depression. Neuroscience 90, 737-745.
53. Zhang WJ, Tan YF, Yue JT, Vranic M, Wojtowicz JM (2007) Impairment of hippocampal neurogenesis in streptozotocintreated diabetic rats. Acta Neurol Scand 117, 205-210.
54. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM, Mattson MP (2008) Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 11, 309-317.
55. Greig NH, HollowayHW, De Ore KA, Jani D,WangY, Zhou J, Garant MJ, Egan JM (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42, 45-50.
56. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278, 471-478.
57. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32, 221-226.
58. Liu Y, Liu H, Yang J, Liu X, Lu S, Wen T, Xie L, Wang G (2008) Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 153, 796-802.
59. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM. Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-beta; (1- 40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
60. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard- NP, Gerard C, Hama E, Lee HJ, Saido, TC (2001) Metabolic regulation of brain Aβ by neprilysin. Science 292, 1550-1552.
61. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KA, Eckman CB (2006) Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281, 30471-30478.
62. Qiu WQ,Walsh DM,Ye Z,Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulindegrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem 273, 32730-32738.
63. Hu J, Igarashi A, Kamata M, NakagawaH(2001) Angiotensinconverting enzyme degrades Alzheimer amyloid β-peptide (Aβ) retards Aβ aggregation, deposition, fibril formation, and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
64. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, and for the DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240-1250.
65. Pedersen WA, Flynn ER (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 17, 500-506.
66. Leissring MA (2008) The AβCs of Aβ-cleaving Proteases. J Biol Chem 283, 29645-29649.
67. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
68. Oddo S, Billings L,Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-323.
69. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86, 3265-3274.
70. Gilman CP, Perry T, Furukawa K, Greig NH, Egan JM, Mattson MP (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87, 1137-1144.
71. Perry T, Greig NH (2004) A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 5, 565-571.
72. Perry T, Greig NH (2004) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Re 2, 377-385.